36-Month Post-marketing Surveillance and Analysis of Menactra Vaccine in 2-10 Year Olds

Post-licensure Safety Surveillance Study of Routine Use of Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Recipients 2 to 10 Years of Age.

To further characterize the safety profile of Menactra vaccine and to identify any signals of potentially vaccine-related adverse events (AEs) not detected during pre-licensure studies.

Inclusion Criteria:

• Receipt of Menactra vaccine during the study period.

Exclusion Criteria:

• None